Idenix: Barclays Healthcare Conference (Idenix) - Mar 14, 2013 - Anticipated initiation of oral P2 combo (IDX 719+TMC435+RBV) trial for HCV in Q2 2013; Anticipated initiation of P2 combo (IDX719+TMC435+TMC055/r+/-RBV) trial for HCV in Q3 2013; Anticipated completion of P2 combo (IDX719+TMC435+TMC055/r+/-RBV) trial for HCV in Q1 2014; Anticipated IND filing for combo trial (IDX "U" Nuc+IDX719+/-RBV) for HCV in H1 2013; Anticipated initiation of POC study for HCV in H2 2013; Anticipated initiation of P2 study for HCV in Q4 2013
Anticipated IND • Anticipated new P2 trial • Anticipated new trial • Anticipated trial initiation date • Hepatitis C Virus
|